OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedHealthfirstPolicy PO-RE-065v6

Diagnosis of Idiopathic Environmental Intolerance

Customize your policy alerts

Sign up for Healthfirst Policy PO-RE-065v6 alerts

Get alerted when Policy PO-RE-065v6 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage stance for laboratory and diagnostic testing related to idiopathic environmental intolerance (IEI, formerly multiple chemical sensitivity) and describes which tests do not meet coverage criteria; intended for providers and claims reviewers under Healthfirst benefits.

Policy Summary

PayerHealthfirst

PolicyDiagnosis of Idiopathic Environmental Intolerance

Policy CodePolicy PO-RE-065v6

Change TypeClarification and removal of reimbursement section

Effective DateMay 1, 2025

Last ReviewMar 16, 2026

Next Review Date

Key ActionObtain prior authorization before ordering specialized panels or nonstandard laboratory tests listed in the policy.

SourceLink

POLICY UPDATE CHANGES

Breath hydrogen and/or breath methane testing DOES NOT MEET COVERAGE CRITERIA.

Replaced wording 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings' in CC2 and CC3 for clarity of enforcement.

Former Section IV. Reimbursement Policy was removed because it created confusion and had minimal enforcement value.

Breath testExplicitly disallowed

IEI confirmatory testsBroad noncoverage

Micronutrient panelsUnsupported panels

20+References cited

Procedural listCodes enumerated

Coverage Criteria

Not covered testing for IEI

Not covered — the following laboratory tests and profiles do not meet coverage criteria:

General noncoverage for confirmatory testing: Laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) do not meet coverage criteria.

[[chunk 1]]

Screening in asymptomatic/general encounters: For asymptomatic individuals and/or during general encounters without abnormal findings, screening of blood, saliva, serum, plasma, urine, and/or stool for volatile solvents, organic acids, and organophosphates does not meet coverage criteria.

[[chunk 1]]

Profiling for common environmental chemicals: For asymptomatic individuals and/or during general encounters without abnormal findings, profiling of phthalates and parabens, and profiling of chlorinated pesticides (including DDE and DDT) using blood, serum, plasma, saliva, urine, and/or stool samples does not meet coverage criteria.

Policy Summary

PayerHealthfirst

PolicyDiagnosis of Idiopathic Environmental Intolerance

Policy CodePolicy PO-RE-065v6

Change TypeClarification and removal of reimbursement section

Effective DateMay 1, 2025

Last ReviewMar 16, 2026

Next Review Date

Key ActionObtain prior authorization before ordering specialized panels or nonstandard laboratory tests listed in the policy.

SourceLink

On This Page

Coverage considerations and criteria based on professional guidance

Testing and evaluation for IEI/MCS should be guided by clinical criteria and evidence-based recommendations; many professional bodies discourage nonvalidated testing and recommend a conservative, symptom-driven approach.

Clinical basis for testing: Testing should be based on established clinical recognition criteria (chronicity, reproducible exposure-response, low-level triggers, improvement with avoidance, responses to chemically unrelated substances).

1999 Consensus Document

Professional guidance limiting testing: Major specialty statements (eg, AAAAI, ACOEM) advise against routine use of many nonvalidated immune-based or proprietary panels for IEI and recommend avoiding unnecessary or nonvalidated tests.

AAAAI 2006; ACOEM 1999

SIBO and breath testing indications: Gastroenterology guidance (ACG and North American Consensus) suggests breath testing (glucose or lactulose hydrogen/methane) may be appropriate in selected symptomatic patients for evaluation of SIBO, IBS-related symptoms, post-luminal surgery, or methane-associated constipation, with appropriate pretest evaluation and protocol adherence.

North American Consensus; ACG

Regulatory context for proprietary/LDT tests: No FDA-cleared diagnostic tests for IEI were identified; many assays are laboratory-developed tests (LDTs) performed in-house and regulated under CLIA as high-complexity tests, which may lack demonstrated clinical validity.

FDA / LDT context

Edited coverage determinations and clarifications

Policy-level coverage determinations and edits (summary):

Breath hydrogen/methane testing: Breath hydrogen and/or breath methane testing DOES NOT MEET COVERAGE CRITERIA.

Revision history states testing is not allowed under any circumstances.

Wording clarifications for CC2 and CC3: CC2 and CC3 were edited to replace 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings' to clarify enforcement of screening and profiling exclusions.

Revision history edits to clarify enforcement.

Administrative edits: Former reimbursement section was removed for clarity; CPT code description revisions for 83015 and 83018 were noted (effective 1/1/2026).

Administrative edits noted in revision history.

The policy lists an extensive set of laboratory tests and multi‑analyte profiling panels that do not meet coverage criteria when used to diagnose idiopathic environmental intolerance (IEI) or as broad screening in asymptomatic or general encounters. Examples include testing of blood, serum, plasma, saliva, urine, and/or stool for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (including DDE and DDT), and metabolic or nutritional markers such as carnitine, oxidative stress/antioxidant markers, detoxification and methylation markers, lipoic acid, CoQ10, vitamin and mineral sufficiency, and nutritional analysis.

The policy further specifies that testing for metals from various specimen types (blood, serum, urine, cerebrospinal fluid, fingernails, hair, and/or stool), and broad panels marketed for IEI (eg, multi‑analyte micronutrient or exposure profiles) are included in the list of tests that do not meet coverage criteria when ordered to confirm IEI or as part of non‑targeted screening in individuals without abnormal findings.

The policy states that no FDA‑cleared or FDA‑approved diagnostic tests for idiopathic environmental intolerance (IEI) were identified. Many laboratory‑developed tests (LDTs) cited in the IEI context are performed and validated in‑house and are regulated under CLIA as high‑complexity tests rather than approved or cleared by the FDA. Proprietary panels and other vendor‑marketed tests for IEI that lack demonstrated clinical validity or FDA clearance may be excluded or considered investigational under this policy.

Because LDTs for IEI are not FDA‑cleared and clinical validity is not established for many proprietary assays, the policy indicates these tests lack supportive evidence linking results to diagnosis or treatment benefit and therefore do not meet coverage criteria when used to diagnose IEI.

Covered Indications and Initial Evaluation

Targeted routine laboratory evaluation

Covered when guided by clinical evaluation and targeted findings; initial evaluation should prioritize history, exam, and routine laboratory tests.

Initial clinical evaluation: Evaluation should include a targeted history, physical examination, occupational/environmental exposure history, and use of screening questionnaires (eg, EESI, PHQ-9) as clinically indicated.

[[chunk 7]]

Routine baseline laboratory tests: Initial laboratory evaluation may include complete blood count (CBC), serum electrolytes and glucose, and urinalysis; further testing should be guided by reported symptoms and clinical findings.

[[chunk 7]]

Symptom-driven additional testing: Order additional diagnostic tests only when indicated by specific symptoms or specialist guidance (eg, gastroenterology for suspected SIBO or motility disorders).

[[chunk 7]]

Breath hydrogen/methane testing

Breath hydrogen/methane testing may be suggested in selected clinical scenarios when performed per consensus protocols and specialist guidance.

Indication — suspected SIBO: Breath testing (glucose or lactulose hydrogen/methane) is suggested for suspected small intestinal bacterial overgrowth (SIBO) per North American expert consensus; consider the suggested culture threshold (>10^3 c.f.u./ml) if aspirate cultures are used.>10^3 c.f.u./ml

[[chunk 23]]

Indication — symptomatic IBS or motility disorders: Use breath testing in symptomatic patients with IBS or suspected motility disorders when clinically indicated, following ACG guidance (conditional recommendations).

[[chunk 26]]

Indication — post-luminal surgery: Consider breath testing for symptomatic patients with prior luminal abdominal surgery per ACG recommendations.

[[chunk 26]]

Covered indications summary

Referenced literature, commercial test vendors, and materials cited in the policy (these citations do not imply coverage approval).

Micronutrient and vendor citations: Commercial micronutrient and related panels cited include SpectraCell Micronutrient Test Panel and SPECTROX, Genova ONE (Optimal Nutritional Evaluation) FMV, LifeExtension Nutrient Panel, Vibrant Micronutrient Panel, and Genova Organix Comprehensive Profile; these are referenced as examples but are not stated as covered.

[[chunk 36]]

Breath testing literature: Key references for breath testing and SIBO include the North American Consensus on hydrogen and methane-based breath testing and ACG clinical guideline on SIBO; these inform appropriate use recommendations but do not constitute blanket coverage approval.

[[chunk 37],[chunk 38]]

Additional references: Additional cited literature includes reviews on SIBO pathophysiology and clinical implications, nutritional biomarker limitations, and publications on IEI/MCS epidemiology and workplace considerations.

[[chunk 39]]

Coding and Procedural Codes

Applicable laboratory CPT codes (part 1)CPT

82108	Aluminum
82127	Amino acids; single, qualitative, each specimen
82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
82139	Amino acids, 6 or more amino acids, quantitative, each specimen
82300	Cadmium
82379	Carnitine (total and free), quantitative, each specimen
82380	Carotene
82441	Chlorinated hydrocarbons, screen
82495	Chromium
82507	Citrate

1–10 of 15

1/2

Applicable laboratory CPT codes (part 2)CPT

82710	Fat or lipids, feces; quantitative
82715	Fat differential, feces, quantitative
82726	Very long chain fatty acids
82978	Glutathione
83015	Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); qualitative, any number of analytes
83018	Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); quantitative, each, not elsewhere specified
83150	Homovanillic acid (HVA)
83497	Hydroxyindolacetic acid, 5-(HIAA)
83655	Lead
83735	Magnesium

1–10 of 15

1/2

Applicable laboratory and breath test codes (part 3)CPT | HCPCS

84134	Prealbumin
84255	Selenium
84446	Tocopherol alpha (Vitamin E)
84585	Vanillylmandelic acid (VMA), urine
84590	Vitamin A
84600	Volatiles (eg, acetic anhydride, diethylether)
84630	Zinc
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
86353	Lymphocyte transformation, mitogen or antigen induced blastogenesis
89125	Fat stain, feces, urine, or respiratory secretions

1–10 of 12

1/2

Revised CPT CodesCPT

83015	Code description revised (document notes revision effective 1/1/2026).
83018	Code description revised (document notes revision effective 1/1/2026).

inv-14: SIBO culture threshold — key value

SIBO culture threshold>10^3 c.f.u./ml

Source recommendationThreshold suggested by North American expert consensus for the definition of SIBO

Evidence qualityNoted as low quality of evidence in the consensus guidance

inv-15: Miscellaneous coding note

NoteNo summary text provided in inventory placeholder.

ActionVerify coding or editorial note source before publication.

StatusPlaceholder carried from inventory; requires content or removal.

Provider Actions, Prior Authorization and Documentation

Denial Risk

Denial for confirmatory IEI testing

Requests for laboratory tests intended to confirm a diagnosis of idiopathic environmental intolerance (IEI) will be denied; such confirmatory IEI testing does not meet coverage criteria.

Tests intended to confirm IEI (diagnostic confirmation) are not covered

Denial Risk

Denial for broad screening and profiling

Screening or broad profiling of biologic samples for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (including DDE and DDT), and similar panels for asymptomatic individuals or during encounters without abnormal findings will be denied.

Screening/profiling of blood, serum, plasma, saliva, urine, stool for solvents, organic acids, organophosphates — NOT COVERED
Profiling of phthalates, parabens, chlorinated pesticides — NOT COVERED
Profiling or broad metal testing of blood, urine, CSF, hair, nails, stool for asymptomatic individuals — NOT COVERED

Documentation Required

Required clinical evaluation before specialized testing

Before ordering specialized or proprietary panels related to IEI, providers must perform and document a focused clinical evaluation including history, physical examination, and routine targeted laboratory testing guided by presenting symptoms. Psychiatric screening and an occupational/environmental exposure history should be included when relevant.

Document a history and focused physical exam that links symptoms to exposures or GI/other organ system complaints
Document targeted routine labs when indicated (eg, CBC, serum electrolytes, glucose, urinalysis)
Include an occupational/environmental exposure history and, where applicable, a psychiatric screen (eg, PHQ-9)

Documentation Required

Required clinical documentation to support testing

Requests for specialized testing must be supported by clinical documentation that aligns with consensus recognition criteria for MCS/IEI: chronicity of symptoms, reproducible symptoms with repeated exposure, symptom provocation at low exposure levels, improvement on removal of the agent, and responses to unrelated substances where applicable. Documentation should also note symptom duration, specific triggers, and prior conservative management steps.

Evidence of chronic symptoms and reproducible association with exposures
Description of specific triggers and temporal relationship to exposure
Documentation that symptoms abate with removal of suspected agents
Record of prior conservative management and rationale for advancing to specialized testing

Step Therapy

Stepwise clinical approach prior to advanced testing

Adopt a stepwise clinical approach prior to ordering advanced or proprietary tests: prioritize establishing a therapeutic alliance, conservative management, and avoidance of unnecessary testing. Refer to specialists (eg, gastroenterology for suspected SIBO, allergy/immunology for relevant allergic workup, psychiatry when comorbidity suspected) when clinically indicated.

Attempt symptom-directed conservative management and document response before advanced testing
Refer to appropriate specialist when initial evaluation suggests alternative diagnoses (eg, SIBO, lactose intolerance)
Avoid proprietary multi-analyte panels for nonspecific symptoms unless clear clinical indication is documented

Note

Code description revisions noted

Code descriptions for certain laboratory codes (eg, CPT 83015, 83018) were revised effective 1/1/2026. These coding description changes do not alter prior authorization or coverage requirements under this policy; providers should ensure accurate coding but note that coverage determinations remain based on the clinical criteria and exclusions in this policy.

Revised CPT descriptions effective 01/01/2026 for 83015 and 83018 — coding updates only
Prior authorization and coverage requirements are unchanged despite code description revisions

Ordering Requirements and Responsible Providers

Note

Ordering must be driven by targeted clinical findings and exposure history

Order targeted testing only when supported by focused clinical findings; include occupational/environmental exposure history and consider psychiatric screening (eg, PHQ‑9) or EESI as clinically indicated before ordering specialized tests.

Use screening questionnaires and document exposure history to support the clinical rationale

Note

Order tests per specialist guidance and indication

Order specialized tests based on specialist guidance and specific clinical indications (for example, consult gastroenterology for breath testing and follow ACG/North American consensus recommendations for SIBO testing).

Reserve breath testing for symptomatic patients per gastroenterology guidance (eg, IBS, motility disorders, prior luminal surgery, methane‑associated constipation)

Note

No explicit ordering‑provider restrictions specified

The policy does not specify explicit restrictions on which provider types may order tests.

No ordering‑provider limitations are stated in the cited policy sections

Not Covered

Laboratory tests and multi‑analyte panels performed to confirm idiopathic environmental intolerance or to broadly screen biologic samples for exposures are listed as not covered. This includes testing for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (eg, DDE, DDT), and metabolic/nutritional markers (eg, carnitine, oxidative stress, detoxification, methylation markers, lipoic acid, CoQ10, vitamin and mineral sufficiency).

The policy clarifies these items do not meet coverage criteria when ordered to diagnose IEI or when used for non‑targeted screening in asymptomatic individuals or during general encounters without abnormal findings.

The policy identifies nonvalidated immune‑based tests and proprietary multi‑analyte panels that lack demonstrated clinical validity or FDA clearance as not covered when used to diagnose IEI. Specialty guidance (eg, AAAAI) has specifically discouraged many of these immune‑based assays as lacking validity or usefulness.

Because many such tests are laboratory‑developed (LDTs) and not FDA‑cleared, the absence of established clinical validity and consensus support is a basis for considering these proprietary panels not covered or investigational under the policy.

The policy explicitly lists breath hydrogen and/or breath methane testing (CPT 91065) as not covered for the diagnosis of IEI. The revision history clarifies that breath hydrogen/methane testing does not meet coverage criteria and is disallowed under any circumstances for IEI claims.

Providers should expect claims for breath hydrogen or methane testing submitted to support an IEI diagnosis to be denied per this policy determination.

Background and Rationale

Idiopathic environmental intolerance (IEI), previously termed multiple chemical sensitivity (MCS), is described as a subjective condition characterized by recurrent, nonspecific symptoms attributed to low‑level exposures to chemical, biologic, or physical agents in the absence of consistent objective diagnostic findings or laboratory tests. The policy notes symptom overlap with common conditions (eg, anxiety, fatigue, gastrointestinal complaints, headaches) and a high prevalence of psychiatric comorbidity in this population.

Because there is no reliable laboratory signature for IEI and many proposed tests and panels lack validation, the policy concludes that laboratory testing intended to confirm IEI is not supported by the available scientific literature and therefore does not meet coverage criteria.

Definitions

inv-30: Idiopathic environmental intolerance (IEI) definition

DefinitionA subjective condition characterized by recurrent, nonspecific symptoms attributed to low levels of chemical, biologic, or physical agents in the absence of consistent objective diagnostic findings or laboratory tests.

Alternate nameFormerly called multiple chemical sensitivity (MCS)

Clinical contextSymptoms overlap with common conditions (eg, anxiety, fatigue, GI complaints, headaches) and psychiatric comorbidity is frequent.

inv-31: 1999 Consensus Document recognition criteria

Recognition criteria (1999 Consensus)Chronic condition; reproducible symptoms with repeated chemical exposure; low exposure levels trigger symptoms; removal of agents leads to symptom subsidence; responses to chemically unrelated substances.

Usage1999 Consensus Document is the most widely used criteria for recognition of MCS/IEI.

PurposeIntended to establish consensus criteria for clinical recognition of MCS/IEI.

inv-32: LDT — definition and regulatory context

DefinitionLaboratory-developed tests (LDTs) are tests developed and performed in-house by laboratories and are regulated by CMS under CLIA as high-complexity tests.

FDA statusLDTs are not approved or cleared by the U.S. Food and Drug Administration.

Regulatory implicationAbsence of FDA approval may be a basis for noncoverage scrutiny when clinical validity is unsupported; labs must validate and perform these tests in-house under CLIA requirements.

inv-33: IEI / Multiple Chemical Sensitivity — cross-reference

Cross-referencesIEI / Multiple Chemical Sensitivity is referenced in position statements and consensus documents from multiple specialty societies and review articles (eg, ACOEM, AAAAI, North American Consensus, ACG).

Representative sourcesACOEM position statement (1999); AAAAI position statements; North American Consensus on breath testing; multiple review articles cited in references.

Clinical relevanceThese position statements and consensus documents inform recognition criteria and guidance discouraging nonvalidated testing for IEI.

Revision History

2025-12-03policy_revisionLatest

Reviewed and updated background, guidelines, recommendations, and evidence base; clarified wording in CC2 and CC3 to replace 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings'; edited CC4-CC6 and CC8 for consistency; explicitly stated that breath hydrogen and/or breath methane testing does not meet coverage criteria (disallowed under any circumstances).

2025-12-03administrative_removal

Removed former Section IV. Reimbursement Policy because it created confusion and provided minimal enforcement value across clients.

2025-12-03coding_update_notice

Noted revised code descriptions for CPT codes 83015 and 83018 effective 2026-01-01.

2024-12-04review_update

Reviewed and updated background, guidelines, recommendations, and evidence base; literature review did not necessitate modifications to coverage criteria.

Diagnosis of Idiopathic Environmental Intolerance

Sign up for Healthfirst Policy PO-RE-065v6 alerts

Coverage Criteria

Covered Indications and Initial Evaluation

Coding and Procedural Codes

Provider Actions, Prior Authorization and Documentation

Ordering Requirements and Responsible Providers

Not Covered

Background and Rationale

Definitions

Frequency Limits

Revision History